136 related articles for article (PubMed ID: 37795911)
1. Characteristics of adverse drug reactions induced by flutamide and bicalutamide: a real-world pharmacovigilance study using FAERS.
Sun Y; Xu T; Zhu S; Xu H
Expert Opin Drug Saf; 2024 Mar; 23(3):305-311. PubMed ID: 37795911
[TBL] [Abstract][Full Text] [Related]
2. Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group.
Schellhammer P; Sharifi R; Block N; Soloway M; Venner P; Patterson AL; Sarosdy M; Vogelzang N; Jones J; Kolvenbag G
Urology; 1996 Jan; 47(1A Suppl):54-60; discussion 80-4. PubMed ID: 8560679
[TBL] [Abstract][Full Text] [Related]
3. Spontaneous reporting of hepatotoxicity associated with antiandrogens: data from the Spanish pharmacovigilance system.
Manso G; Thole Z; Salgueiro E; Revuelta P; Hidalgo A
Pharmacoepidemiol Drug Saf; 2006 Apr; 15(4):253-9. PubMed ID: 16294367
[TBL] [Abstract][Full Text] [Related]
4. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study Group.
Schellhammer PF; Sharifi R; Block NL; Soloway MS; Venner PM; Patterson AL; Sarosdy MF; Vogelzang NJ; Chen Y; Kolvenbag GJ
Cancer; 1996 Nov; 78(10):2164-9. PubMed ID: 8918410
[TBL] [Abstract][Full Text] [Related]
5. Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade.
Schellhammer PF; Venner P; Haas GP; Small EJ; Nieh PT; Seabaugh DR; Patterson AL; Klein E; Wajsman Z; Furr B; Chen Y; Kolvenbag GJ
J Urol; 1997 May; 157(5):1731-5. PubMed ID: 9112515
[TBL] [Abstract][Full Text] [Related]
6. Is combined androgen blockade with bicalutamide cost-effective compared with combined androgen blockade with flutamide?
Ramsey S; Veenstra D; Clarke L; Gandhi S; Hirsch M; Penson D
Urology; 2005 Oct; 66(4):835-9. PubMed ID: 16230148
[TBL] [Abstract][Full Text] [Related]
7. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group.
Schellhammer P; Sharifi R; Block N; Soloway M; Venner P; Patterson AL; Sarosdy M; Vogelzang N; Jones J; Kolvenbag G
Urology; 1995 May; 45(5):745-52. PubMed ID: 7538237
[TBL] [Abstract][Full Text] [Related]
8. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group.
Schellhammer PF; Sharifi R; Block NL; Soloway MS; Venner PM; Patterson AL; Sarosdy MF; Vogelzang NJ; Schellenger JJ; Kolvenbag GJ
Urology; 1997 Sep; 50(3):330-6. PubMed ID: 9301693
[TBL] [Abstract][Full Text] [Related]
9. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease.
Scher HI; Liebertz C; Kelly WK; Mazumdar M; Brett C; Schwartz L; Kolvenbag G; Shapiro L; Schwartz M
J Clin Oncol; 1997 Aug; 15(8):2928-38. PubMed ID: 9256137
[TBL] [Abstract][Full Text] [Related]
10. [Effect of change to flutamide for prostate cancer patient who developed breast pain during bicalutamide treatment (BIP-F study)].
Kitamura Y; Okuno H; Sakura Y; Manabe Y; Masuda N; Ito H; Mishina M; Taoka R; Terai A; Sugimoto M; Kakehi Y
Hinyokika Kiyo; 2014 Jan; 60(1):17-23. PubMed ID: 24594768
[TBL] [Abstract][Full Text] [Related]
11. Exploratory analysis on the effect of race on clinical outcome in patients with advanced prostate cancer receiving bicalutamide or flutamide, each in combination with LHRH analogues. The Casodex Combination Study Group.
McLeod DG; Schellhammer PF; Vogelzang NJ; Soloway MS; Sharifi R; Block NL; Venner PM; Patterson AL; Sarosdy MF; Kelley RP; Kolvenbag GJ
Prostate; 1999 Sep; 40(4):218-24. PubMed ID: 10420149
[TBL] [Abstract][Full Text] [Related]
12. The preclinical development of bicalutamide: pharmacodynamics and mechanism of action.
Furr BJ; Tucker H
Urology; 1996 Jan; 47(1A Suppl):13-25; discussion 29-32. PubMed ID: 8560673
[TBL] [Abstract][Full Text] [Related]
13. Abrocitinib-associated adverse events: a real-world pharmacovigilance study using the FAERS database.
Sun Y; Xu T; Zhu S; Xu H
Expert Opin Drug Saf; 2024 May; ():1-7. PubMed ID: 38739473
[TBL] [Abstract][Full Text] [Related]
14. A Randomized Control Trial Comparing the Efficacy of Antiandrogen Monotherapy: Flutamide vs. Bicalutamide.
Nakai Y; Tanaka N; Anai S; Miyake M; Tatsumi Y; Fujimoto K
Horm Cancer; 2015 Aug; 6(4):161-7. PubMed ID: 26024831
[TBL] [Abstract][Full Text] [Related]
15. A case of advanced prostate cancer controlled for the long term by flutamide after bicalutamide failure.
Muramatsu T; Funahashi Y; Yamamoto A; Sassa N; Matsukawa Y; Gotoh M
Nagoya J Med Sci; 2019 Nov; 81(4):707-710. PubMed ID: 31849389
[TBL] [Abstract][Full Text] [Related]
16. Adverse Events Associated With Radium-223 in Metastatic Prostate Cancer: Disproportionality Analysis of FDA Data Reflecting Worldwide Utilization.
Huynh-Le MP; Shults RC; Connor MJ; Hattangadi-Gluth JA
Clin Genitourin Cancer; 2020 Jun; 18(3):192-200.e2. PubMed ID: 31902714
[TBL] [Abstract][Full Text] [Related]
17. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study.
Boccardo F; Rubagotti A; Barichello M; Battaglia M; Carmignani G; Comeri G; Conti G; Cruciani G; Dammino S; Delliponti U; Ditonno P; Ferraris V; Lilliu S; Montefiore F; Portoghese F; Spano G
J Clin Oncol; 1999 Jul; 17(7):2027-38. PubMed ID: 10561254
[TBL] [Abstract][Full Text] [Related]
18. [The role of bicalutamide in the treatment of prostate cancer].
Stav SY; Segal G
Harefuah; 2002 Apr; 141(4):379-83, 408, 407. PubMed ID: 12017896
[TBL] [Abstract][Full Text] [Related]
19. Hydroxyflutamide enhances cellular sensitivity to 5-fluorouracil by suppressing thymidylate synthase expression in bicalutamide-resistant human prostate cancer cells.
Kawabata R; Oie S; Oka T; Takahashi M; Kanayama H; Itoh K
Int J Oncol; 2011 Mar; 38(3):665-76. PubMed ID: 21243325
[TBL] [Abstract][Full Text] [Related]
20. A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib.
Yin Y; Shu Y; Zhu J; Li F; Li J
Sci Rep; 2022 Nov; 12(1):19555. PubMed ID: 36380085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
